Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium (U24)

The summary for the Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium (U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium (U24): The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop a Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Collaborative Consortium. The Collaborative Consortium will be responsible for developing an infrastructure upon which a future SCD in SSA Research Network can be built. This Collaborative Consortium will be comprised of a Consortium Hub (applicant institution) and at least two Collaborating Sites located in sub-Saharan African countries separate from that of the applicant institution.This program is intended to establish an SCD resource that can be shared across the collaborative consortium to enhance future research endeavors.

Federal Grant Title:	Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium (U24)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-17-006
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.839
CFDA Descriptions:	Blood Diseases and Resources Research
Current Application Deadline:	Feb 26, 2016
Original Application Deadline:	Feb 26, 2016
Posted Date:	Sep 1, 2015
Creation Date:	Sep 1, 2015
Archive Date:	Mar 28, 2016
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:	1
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) in sub-Saharan Africa are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations in sub-Saharan Africa are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-17-006.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immu...; • New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional); • Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...; • Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional); • Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional); • Improved Therapy for Hemophilia and Hereditary Bleeding Disorders; • Clinical Hematology Research Career Development Program (K12); • Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...